Kidswell Bio Corporation
| Market Cap | 12.5B |
| P/E Ratio | 37.06 |
| P/B Ratio | 6.49 |
| EPS | -0.52 |
| Dividend Yield | - |
| D/E Ratio | 3.97 |
| Current Ratio | 1.55 |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
Business Overview
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
| Fiscal Year | 2025 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | Kidswell Bio Corporation |
| Ticker | 4584 |
| Exchange | TSE |
| Sector | Pharmaceutical |
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Fiscal Year | 2025 |
| Currency | JPY |
| Market Cap | 12.5B |
| Revenue | 5.1B |
| Net Income | -21.1M |
| P/E Ratio | 37.06 |
| EPS | -0.52 |
| Net Margin | -0.4% |
| ROE | -1.5% |
| Dividend Yield | - |
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.